Sequential immunotherapy using interleukin-1 followed by interleukin-2 of ascitic MOPC104E-bearing mice.
This study shows that intraperitoneal injection of interleukin-1 (IL-1), followed by interleukin-2 (IL-2), can effectively eradicate murine ascitic tumor cells. This antitumor effect of IL-1 and IL-2 was abolished when administration of IL-2 preceded that of IL-1. Solid tumors inoculated subcutaneously (s.c.) into the back of mice were also sensitive to this combined i.p. therapy, indicating a systemically-operating antitumor mechanism. Splenocytes from tumor-bearing mice treated with IL-1 followed by IL-2 showed a strong tumor-neutralizing activity. The population responsible proved to be Lyt2.2 (CD8)-positive cells.
Harada
T
T
First Department of Surgery, Faculty of Medicine, Kyoto University, Japan.
Kan
N
N
Okino
T
T
Ichinose
Y
Y
Moriguchi
Y
Y
Li
L
L
Sugie
T
T
Ohgaki
K
K
Imamura
M
M
D000818:Animals; D002478:Cells, Cultured; D007375:Interleukin-1 / Q000008:administration & dosage*; D007376:Interleukin-2 / Q000008:administration & dosage*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009374:Neoplasms, Experimental / Q000628:therapy*; D010954:Plasmacytoma / Q000628:therapy; D013154:Spleen / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology
D007375:Interleukin-1; D007376:Interleukin-2